Unicycive Therapeutics, Inc.
UNCY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $0 |
| % Growth | -100% | -29% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $1 | $1 | $0 |
| % Margin | – | 100% | 100% | – |
| R&D Expenses | $20 | $13 | $12 | $6 |
| G&A Expenses | $12 | $9 | $7 | $3 |
| SG&A Expenses | $12 | $9 | $7 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $32 | $21 | $19 | $9 |
| Operating Income | -$32 | -$21 | -$18 | -$9 |
| % Margin | – | -3,077.6% | -1,898.2% | – |
| Other Income/Exp. Net | -$5 | -$10 | -$0 | -$1 |
| Pre-Tax Income | -$37 | -$31 | -$18 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$37 | -$31 | -$18 | -$10 |
| % Margin | – | -4,525% | -1,898.8% | – |
| EPS | -5.6 | -1.28 | -1.2 | -8.6 |
| % Growth | -337.5% | -6.7% | 86% | – |
| EPS Diluted | -5.6 | -1.28 | -1.2 | -8.6 |
| Weighted Avg Shares Out | 7 | 2 | 2 | 1 |
| Weighted Avg Shares Out Dil | 7 | 2 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$36 | -$30 | -$18 | -$9 |
| % Margin | – | -4,470.8% | -1,881.3% | – |